Mingyuan Medicare purchase 75% of Shanghai Kang Pei Bio-Medical

Hong Kong-listed healthcare solutions provider Mingyuan Medicare Development Co., Ltd. (SEHK: 0233) today announces that it has complete the purchase of a 75% stake in Shanghai Kang Pei Bio-Medical Co., Ltd., with a total investment of CNY 310 million in cash.

Shanghai Kang Pei Bio-Medical has established 12 medical centers in Shanghai, Tianjin, Chengdu, and Taiyuan by far, and the total number of its customers has exceeded 400,000 per year, said people familiar with the matter.

Mingyuan Medicare Development Company Limited has been listed on the main board of The Hong Kong Stock Exchange since September 2002. Mingyuan Medicare principally engages in provision of innovative medicare solutions for the early detection and prevention of diseases particularly in China. With “Care for Health, Passion for Life” as our motto, the Company dedicates to develop and to apply approved and proven biomedical products and services for use in the early detection and prevention of diseases and including cancer. The Company set its goal to become a leading and comprehensive biomedical solutions provider in the world.

Originally Posted: Top Diagnosis